Market capitalization | CHF35.28b |
Enterprise Value | CHF37.12b |
P/E (TTM) P/E ratio | 62.78 |
EV/FCF (TTM) EV/FCF | 789.72 |
EV/Sales (TTM) EV/Sales | 5.54 |
P/S ratio (TTM) P/S ratio | 5.27 |
P/B ratio (TTM) P/B ratio | 3.77 |
Dividend yield | 0.72% |
Last dividend (FY23) | CHF4.00 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
19 Analysts have issued a Lonza forecast:
19 Analysts have issued a Lonza forecast:
Jun '24 |
+/-
%
|
||
Revenue | 6,696 6,696 |
6%
6%
|
|
Gross Profit | 1,956 1,956 |
17%
17%
|
|
EBITDA | 2,064 2,064 |
2%
2%
|
EBIT (Operating Income) EBIT | 1,433 1,433 |
5%
5%
|
Net Profit | 573 573 |
49%
49%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.
Head office | Switzerland |
CEO | Wolfgang Wienand |
Employees | 18,000 |
Founded | 1897 |
Website | www.lonza.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.